Difference Between Generic ANDA and 505(b)(2) Submissions
In the pharmaceutical industry, both generic (ANDA) and 505(b)(2) submissions are key regulatory pathways, but they serve different purposes.
Generic (ANDA): This is for drugs that are bioequivalent to an already approved product. ANDA submissions must show the drug is the same in dosage, form, strength, and administration route as the reference drug. No new clinical data are required.
505(b)(2): This is a hybrid pathway allowing approval of drugs that are similar but not identical to an existing product. Unlike ANDA, it can include new indications, formulations, or delivery methods and may require new clinical data to support these changes.
Both pathways offer unique routes to market with varying levels of innovation and regulatory complexity. The table below provides a simple comparison of both pathways with some examples.
Read also:
Resource Person: Bhupesh Pratap
